Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 oral azacitidine versus placebo in lower-risk myelodysplastic syndromes with transfusion-dependent anemia and thrombocytopenia
NL-OMON47302Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Oral azacitidine plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Red blood cell transfusion independence. Started May 2015; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON47302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47302.